UA104127C2 - Sirtuin modulating imidazothiazole compounds - Google Patents
Sirtuin modulating imidazothiazole compoundsInfo
- Publication number
- UA104127C2 UA104127C2 UAA201000211A UAA201000211A UA104127C2 UA 104127 C2 UA104127 C2 UA 104127C2 UA A201000211 A UAA201000211 A UA A201000211A UA A201000211 A UAA201000211 A UA A201000211A UA 104127 C2 UA104127 C2 UA 104127C2
- Authority
- UA
- Ukraine
- Prior art keywords
- diseases
- sirtuin
- disorders
- modulating
- sirtuin modulating
- Prior art date
Links
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical class C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 title 1
- 102000011990 Sirtuin Human genes 0.000 title 1
- 108050002485 Sirtuin Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Данное изобретение касается новых модулирующих сиртуин соединений и способов их применения.Модулирующие сиртуин соединения можно использовать для увеличения продолжительности жизни клетки и лечения и/или профилактики широкого ряда заболеваний или нарушений, например заболеваний и нарушений, связанных со старением или стрессом, диабета, ожирения, нейродегенеративных заболеваний, сердечно-сосудистого заболевания, нарушения свертывания крови, воспаления, злокачественного заболевания и/или гиперемии, а также заболеваний или нарушений, при которых повышенная митохондриальная активность будет иметь положительный эффект.Также описываются композиции, которые содержат модулируюющее сиртуин соединение в комбинации с другим лекарственным средством.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93663307P | 2007-06-20 | 2007-06-20 | |
PCT/US2008/007771 WO2008156866A1 (en) | 2007-06-20 | 2008-06-20 | Sirtuin modulating imidazothiazole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
UA104127C2 true UA104127C2 (en) | 2014-01-10 |
Family
ID=39810276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201000211A UA104127C2 (en) | 2007-06-20 | 2008-06-20 | Sirtuin modulating imidazothiazole compounds |
Country Status (26)
Country | Link |
---|---|
US (2) | US7829556B2 (ru) |
EP (1) | EP2167510B1 (ru) |
JP (1) | JP5281081B2 (ru) |
KR (1) | KR101525268B1 (ru) |
CN (1) | CN101874031B (ru) |
AR (1) | AR067106A1 (ru) |
AU (1) | AU2008266746B2 (ru) |
BR (1) | BRPI0813653A2 (ru) |
CA (1) | CA2692099C (ru) |
CL (1) | CL2008001821A1 (ru) |
CO (1) | CO6261382A2 (ru) |
CR (1) | CR11231A (ru) |
DO (1) | DOP2009000283A (ru) |
EA (1) | EA018182B1 (ru) |
ES (1) | ES2534544T3 (ru) |
IL (1) | IL202729A (ru) |
MA (1) | MA31568B1 (ru) |
MX (1) | MX2009013976A (ru) |
MY (1) | MY149316A (ru) |
NZ (1) | NZ581989A (ru) |
PE (1) | PE20090423A1 (ru) |
TW (1) | TW200918542A (ru) |
UA (1) | UA104127C2 (ru) |
UY (1) | UY31170A1 (ru) |
WO (1) | WO2008156866A1 (ru) |
ZA (1) | ZA200908882B (ru) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
CA2599989A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
CA2617532A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds |
WO2007041643A1 (en) * | 2005-10-03 | 2007-04-12 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
CL2008001821A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
CL2008001822A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
US8391970B2 (en) * | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
WO2009099643A1 (en) * | 2008-02-07 | 2009-08-13 | The J. David Gladstone Institutes | Use of sirt1 activators or inhibitors to modulate an immune response |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
MX2010012010A (es) | 2008-05-01 | 2010-11-30 | Sirtris Pharmaceuticals Inc | Quinolinas y analogos relacionados como moduladores de sirtuin. |
JP5758292B2 (ja) * | 2008-07-03 | 2015-08-05 | サートリス ファーマシューティカルズ, インコーポレイテッド | サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体 |
US9326986B2 (en) | 2008-09-29 | 2016-05-03 | Glaxosmithkline Llc | Quinazolinone, quinolone and related analogs as sirtuin modulators |
CN102215909B (zh) | 2008-11-18 | 2014-09-10 | 赛博恩特医疗器械公司 | 优化用于消炎刺激的电极放置的装置和方法 |
JP2012511048A (ja) | 2008-12-08 | 2012-05-17 | ノースウェスタン ユニバーシティ | Hsf−1の改変方法 |
UA104447C2 (ru) | 2008-12-19 | 2014-02-10 | Сіртріз Фармасьютікалз, Інк. | Тиазолопиридиновые соединения, модулирующие сиртуин |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) * | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
WO2011028763A2 (en) * | 2009-09-01 | 2011-03-10 | Setpoint Medical Corporation | Prescription pad for treatment of inflammatory disorders |
US9556201B2 (en) | 2009-10-29 | 2017-01-31 | Glaxosmithkline Llc | Bicyclic pyridines and analogs as sirtuin modulators |
EA201290194A1 (ru) | 2009-11-06 | 2013-04-30 | Дзе Дж. Дейвид Гладстоун Инститьютс | Способы и композиции для модулирования уровня тау-полипептида |
US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) * | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
EP3636314B1 (en) | 2009-12-23 | 2021-09-08 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
US20130102009A1 (en) | 2010-04-15 | 2013-04-25 | Han Dai | Sirtuin activators and activation assays |
RU2018110642A (ru) | 2010-05-03 | 2019-02-27 | Курна, Инк. | Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt) |
US20130171125A1 (en) * | 2010-05-11 | 2013-07-04 | National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DDS), U.S. Government | Methods for the Regulation of Cellular Metabolism Through the Modulation of SIRT3 Activity |
CN103391777A (zh) | 2011-02-02 | 2013-11-13 | 普林斯顿大学理事会 | 作为病毒产生调节剂的去乙酰化酶调节剂 |
US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
RU2631597C2 (ru) | 2011-07-15 | 2017-09-25 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
WO2014078459A1 (en) | 2012-11-13 | 2014-05-22 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
RU2015143836A (ru) | 2013-03-15 | 2017-04-27 | Нусерт Сайенсиз, Инк. | Лейцин и никотиновая кислота для снижения уровня липидов |
WO2015002892A1 (en) * | 2013-07-01 | 2015-01-08 | Meier Joshua Abraham | Methods of treating diseases by modulating mitochondrial dna deletions |
AU2015222754B2 (en) | 2014-02-27 | 2020-06-25 | Nusirt Sciences Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
AU2015270130A1 (en) | 2014-06-02 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
AU2015270090A1 (en) | 2014-06-06 | 2016-12-22 | Glaxosmithkline Intellectual Property (No.2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
KR101839688B1 (ko) | 2015-08-21 | 2018-03-19 | 중앙대학교 산학협력단 | 이미다조티아졸 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 의약적 용도 |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
WO2017123161A1 (en) * | 2016-01-15 | 2017-07-20 | Agency For Science, Technology And Research | Inhibition of intracellular growth of mycobacterium species and its applications |
WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
CN114904142A (zh) | 2016-01-20 | 2022-08-16 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
JP6727317B2 (ja) | 2016-02-22 | 2020-07-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 肝臓の再生を向上させるための方法 |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
CN109700790A (zh) * | 2018-12-28 | 2019-05-03 | 中南大学湘雅医院 | 一种靶向AQP3的抗皮肤衰老药物Butein |
CN111000854B (zh) * | 2019-12-30 | 2023-06-09 | 昆药集团股份有限公司 | 曲札茋苷在制备治疗和/或预防非酒精性脂肪肝病产品中的应用 |
KR20230012585A (ko) | 2020-05-21 | 2023-01-26 | 더 파인스타인 인스티튜츠 포 메디칼 리서치 | 미주 신경 자극을 위한 시스템들 및 방법들 |
WO2023244862A1 (en) * | 2022-06-17 | 2023-12-21 | Codagen Biosciences, Inc. | Sirtuin modulating compounds, including sirtuin activating compounds, and applications thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1108698B (de) | 1959-09-03 | 1961-06-15 | Hoechst Ag | Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen |
US3517007A (en) * | 1968-04-05 | 1970-06-23 | American Home Prod | 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds |
ZA735753B (en) | 1972-09-14 | 1974-07-31 | American Cyanamid Co | Resolution of 6-substituted amino phenyl-2,3,5,6-tetrahydro(2,1-b)thiadiazoles |
US4018932A (en) * | 1975-11-03 | 1977-04-19 | American Cyanamid Company | Anthelmintic pour-on formulations for topical use on domestic and farm animals |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4939133A (en) * | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
JPH0576084A (ja) | 1991-09-11 | 1993-03-26 | Matsushita Electric Ind Co Ltd | 遠隔表示装置 |
JPH05289689A (ja) | 1992-04-06 | 1993-11-05 | Sanyo Electric Co Ltd | 可搬性規則音声合成装置 |
JPH07291976A (ja) | 1994-04-27 | 1995-11-07 | Otsuka Pharmaceut Factory Inc | イミダゾ〔2,1−b〕チアゾール誘導体 |
US6653309B1 (en) * | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
CA2450555A1 (en) * | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
EA007339B1 (ru) | 2001-07-27 | 2006-08-25 | Кьюэрис, Инк. | Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ |
HUP0103987A3 (en) | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
HUP0103986A2 (hu) | 2001-09-28 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
JP2005298333A (ja) | 2001-11-15 | 2005-10-27 | Meiji Seika Kaisha Ltd | 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤 |
BRPI0408251A (pt) * | 2003-03-11 | 2006-03-01 | Pfizer Prod Inc | compostos de pirazina como inibidores do fator de crescimento transformante (tgf) |
EP1605967A1 (en) | 2003-03-13 | 2005-12-21 | Novo Nordisk A/S | Novel nph insulin preparations |
ZA200605248B (en) | 2003-12-15 | 2007-10-31 | Japan Tobacco Inc | Cyclopropane compounds and pharmaceutical use thereof |
AU2005207029B2 (en) | 2004-01-20 | 2011-09-01 | Brigham Young University | Novel sirtuin activating compounds and methods for making the same |
NZ551340A (en) * | 2004-04-22 | 2010-10-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder |
AU2005257883A1 (en) * | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
CA2599989A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
AU2006244203B2 (en) | 2005-05-09 | 2012-05-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
CA2617532A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds |
US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
CL2008001822A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras. |
CL2008001821A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
JP2011503066A (ja) | 2007-11-08 | 2011-01-27 | サートリス ファーマシューティカルズ, インコーポレイテッド | 可溶化チアゾロピリジン誘導体 |
US20100168084A1 (en) * | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2008
- 2008-06-19 CL CL2008001821A patent/CL2008001821A1/es unknown
- 2008-06-19 TW TW097122811A patent/TW200918542A/zh unknown
- 2008-06-20 ES ES08768696.0T patent/ES2534544T3/es active Active
- 2008-06-20 EA EA201070034A patent/EA018182B1/ru not_active IP Right Cessation
- 2008-06-20 MY MYPI20095422A patent/MY149316A/en unknown
- 2008-06-20 CN CN2008801034489A patent/CN101874031B/zh not_active Expired - Fee Related
- 2008-06-20 US US12/214,804 patent/US7829556B2/en not_active Expired - Fee Related
- 2008-06-20 BR BRPI0813653-0A2A patent/BRPI0813653A2/pt not_active Application Discontinuation
- 2008-06-20 UY UY31170A patent/UY31170A1/es not_active Application Discontinuation
- 2008-06-20 AU AU2008266746A patent/AU2008266746B2/en not_active Ceased
- 2008-06-20 UA UAA201000211A patent/UA104127C2/ru unknown
- 2008-06-20 AR ARP080102662A patent/AR067106A1/es unknown
- 2008-06-20 EP EP08768696.0A patent/EP2167510B1/en active Active
- 2008-06-20 JP JP2010513266A patent/JP5281081B2/ja not_active Expired - Fee Related
- 2008-06-20 KR KR1020107000398A patent/KR101525268B1/ko not_active IP Right Cessation
- 2008-06-20 CA CA2692099A patent/CA2692099C/en not_active Expired - Fee Related
- 2008-06-20 PE PE2008001057A patent/PE20090423A1/es active IP Right Grant
- 2008-06-20 NZ NZ581989A patent/NZ581989A/en not_active IP Right Cessation
- 2008-06-20 MX MX2009013976A patent/MX2009013976A/es active IP Right Grant
- 2008-06-20 WO PCT/US2008/007771 patent/WO2008156866A1/en active Application Filing
-
2009
- 2009-12-11 DO DO2009000283A patent/DOP2009000283A/es unknown
- 2009-12-14 IL IL202729A patent/IL202729A/en not_active IP Right Cessation
- 2009-12-14 ZA ZA200908882A patent/ZA200908882B/xx unknown
-
2010
- 2010-01-08 CO CO10001888A patent/CO6261382A2/es active IP Right Grant
- 2010-01-15 MA MA32518A patent/MA31568B1/fr unknown
- 2010-01-20 CR CR11231A patent/CR11231A/es unknown
- 2010-09-27 US US12/891,667 patent/US8247565B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009013976A (es) | Compuestos imidazotiazol moduladores de sirtuina. | |
MX2009013977A (es) | Compuestos de tiazolopiridina moduladores de sirtuinas. | |
MY160006A (en) | Thiazolopyridine sirtuin modulating compounds | |
IN2012DN03799A (ru) | ||
EP2344475A4 (en) | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE | |
MX2010012961A (es) | Imidazopiridina y analogos relacionados como moduladores de sirtuina. | |
WO2009134973A8 (en) | Quinolines and related analogs as sirtuin modulators | |
MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
MX2011006084A (es) | Isoindolinona y analogos relacionados como moduladores de sirtuina. | |
MX2010004965A (es) | Derivados de amida como moduladores de la sirtuina. | |
WO2006094209A3 (en) | N-benzimidazolylalkyl-substituted amide sirtuin modulators | |
MX2010005186A (es) | Tiazolopiridinas solubilizadas. | |
WO2006094210A3 (en) | Tetrahydroquinoxalinone sirtuin modulators | |
MX2011009213A (es) | Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina. | |
WO2007019344A8 (en) | Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds | |
WO2006094246A3 (en) | N-arylmethyl benzamide sirtuin modulators | |
WO2006078941A3 (en) | Novel sirtuin activating compounds and methods of use thereof | |
WO2006105440A3 (en) | Nicotinamide riboside and analogues thereof | |
WO2014186313A8 (en) | Substituted bridged urea analogs as sirtuin modulators | |
EA201170137A1 (ru) | Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина | |
WO2008100376A3 (en) | Truncation variants of sirt1 and methods of use thereof | |
WO2006094237A3 (en) | Acridine and quinoline dervatives as sirtuin modulators | |
CR9347A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
WO2009085226A3 (en) | Inhibitors of cdc2-like kinases (clks) and methods of use thereof | |
WO2016081692A3 (en) | Substituted bridged urea analogs as sirtuin modulators |